54966-52-8Relevant academic research and scientific papers
From a Designer Drug to the Discovery of Selective Cannabinoid Type 2 Receptor Agonists with Favorable Pharmacokinetic Profiles for the Treatment of Systemic Sclerosis
Jiang, Bei-Er,Jiang, Xingwu,Zhang, Qiansen,Liang, Qiuwen,Qiu, Zi-Liang,Sun, Xiang-Bai,Yang, Jun-Jie,Chen, Si,Yi, Chunyang,Chai, Xiaolei,Liu, Mingyao,Yu, Li-Fang,Lu, Weiqiang,Zhang, Han-Kun
, p. 385 - 403 (2021/02/05)
Synthetic cannabinoids, as exemplified by SDB-001 (1), bind to both CB1 and CB2 receptors and exert cannabimimetic effects similar to (-)-trans-Δ9-tetrahydrocannabinol, the main psychoactive component present in the cannabis plant. As CB1 receptor ligands were found to have severe adverse psychiatric effects, increased attention was turned to exploiting the potential therapeutic value of the CB2 receptor. In our efforts to discover novel and selective CB2 receptor agonists, 1 was selected as a starting point for hit molecule identification and a class of 1H-pyrazole-3-carboxamide derivatives were thus designed, synthesized, and biologically evaluated. Systematic structure-activity relationship investigations resulted in the identification of the most promising compound 66 as a selective CB2 receptor agonist with favorable pharmacokinetic profiles. Especially, 66 treatment significantly attenuated dermal inflammation and fibrosis in a bleomycin-induced mouse model of systemic sclerosis, supporting that CB2 receptor agonists might serve as potential therapeutics for treating systemic sclerosis.
Direct Aldehyde Csp2?H Functionalization through Visible-Light-Mediated Photoredox Catalysis
Vu, Minh Duy,Das, Mrinmoy,Liu, Xue-Wei
supporting information, p. 15899 - 15902 (2017/11/15)
The development of methods for carbon–carbon bond formation under benign conditions is an ongoing challenge for synthetic chemists. In recent years there has been considerable interest in using selective C?H activation as a direct route for generating rea
Design and synthesis of lactam-thiophene carboxylic acids as potent hepatitis C virus polymerase inhibitors
Barnes-Seeman, David,Boiselle, Carri,Capacci-Daniel, Christina,Chopra, Rajiv,Hoffmaster, Keith,Jones, Christopher T.,Kato, Mitsunori,Lin, Kai,Ma, Sue,Pan, Guoyu,Shu, Lei,Wang, Jianling,Whiteman, Leah,Xu, Mei,Zheng, Rui,Fu, Jiping
, p. 3979 - 3985 (2014/11/08)
Herein we report the successful incorporation of a lactam as an amide replacement in the design of hepatitis C virus NS5B Site II thiophene carboxylic acid inhibitors. Optimizing potency in a replicon assay and minimizing potential risk for CYP3A4 induction led to the discovery of inhibitor 22a. This lead compound has a favorable pharmacokinetic profile in rats and dogs.
One-pot synthesis of oxo acid derivatives by RhI-catalyzed chelation-assisted hydroacylation
Jo, Eun-Ae,Jun, Chul-Ho
, p. 2504 - 2507 (2007/10/03)
Various oxo acid derivatives were obtained directly from the reaction of aliphatic and aromatic aldehydes with ω-alkenoic acid derivatives in the presence of rhodium(I) complexes and 2-amino-3-picoline. Wiley-VCH Verlag GmbH & Co. KGaA, 2006.
4-(trans-4-methylcyclohexyl)-4-oxobutyric acid (JTT-608). A new class of antidiabetic agent
Shinkai, Hisashi,Ozeki, Hidekazu,Motomura, Takahisa,Ohta, Takeshi,Furukawa, Noboru,Uchida, Itsuo
, p. 5420 - 5428 (2007/10/03)
During an investigation of drugs for improving the β-cell response to glucose, we found that 4-cyclohexyl-4-oxobutyric acid selectively improved glucose-stimulated insulin release and glucose tolerance in both normal and diabetic rats. A series of 4-cyclo
